- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 248507, 8 pages
Viability Reduction and Rac1 Gene Downregulation of Heterogeneous Ex-Vivo Glioma Acute Slice Infected by the Oncolytic Newcastle Disease Virus Strain V4UPM
1Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
2Department of Pathology, School of Medical Sciences, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia
3Department of Microbiology, Faculty of Veterinary, Universiti Putra Malaysia, 43400 Serdang Selangor, Malaysia
4Department of Biotechnology, Faculty of Agriculture and Biotechnology, Universiti Sultan Zainal Abidin, 21300 Kuala Terengganu, Malaysia
Received 8 July 2012; Accepted 24 February 2013
Academic Editor: Aaron S. Dumont
Copyright © 2013 Zulkifli Mustafa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- G. Wollmann, K. Ozduman, and A. N. van den Pol, “Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates,” Cancer Journal, vol. 18, no. 1, pp. 69–81, 2012.
- F. J. Zemp, J. C. Corredor, X. Lun, D. A. Muruve, and P. A. Forsyth, “Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil,” Cytokine and Growth Factor Reviews, vol. 21, no. 2-3, pp. 103–117, 2010.
- J. Zhong, A. Paul, S. J. Kellie, and G. M. O'Neill, “Mesenchymal migration as a therapeutic target in glioblastoma,” Journal of Oncology, vol. 2010, Article ID 430142, 17 pages, 2010.
- T. C. Liu, E. Galanis, and D. Kirn, “Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress,” Nature Clinical Practice Oncology, vol. 4, no. 2, pp. 101–117, 2007.
- J. N. Parker, D. F. Bauer, J. J. Cody, and J. M. Markert, “Oncolytic viral therapy of malignant glioma,” Neurotherapeutics, vol. 6, no. 3, pp. 558–569, 2009.
- K. A. Parato, D. Senger, P. A. J. Forsyth, and J. C. Bell, “Recent progress in the battle between oncolytic viruses and tumours,” Nature Reviews Cancer, vol. 5, no. 12, pp. 965–976, 2005.
- J. G. Sinkovics and J. C. Horvath, “Newcastle disease virus (NDV): brief history of its oncolytic strains,” Journal of Clinical Virology, vol. 16, no. 1, pp. 1–15, 2000.
- C. Fiola, B. Peeters, P. Fournier, A. Arnold, M. Bucur, and V. Schirrmacher, “Tumor selective replication of newcastle disease virus: association with defects of tumor cells in antiviral defence,” International Journal of Cancer, vol. 119, no. 2, pp. 328–338, 2006.
- S. Krishnamurthy, T. Takimoto, R. A. Scroggs, and A. Portner, “Differentially regulated interferon response determines the outcome of newcastle disease virus infection in normal and tumor cell lines,” Journal of Virology, vol. 80, no. 11, pp. 5145–5155, 2006.
- A. Haseley, C. Alvarez-Breckenridge, A. R. Chaudhury, and B. Kaur, “Advances in oncolytic virus therapy for glioma,” Recent Patents on CNS Drug Discovery, vol. 4, no. 1, pp. 1–13, 2009.
- V. Schirrmacher and P. Fournier, “Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer,” Methods in Molecular Biology, vol. 542, pp. 565–605, 2009.
- A. Phuangsab, R. M. Lorence, K. W. Reichard, M. E. Peeples, and R. J. Walter, “Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration,” Cancer Letters, vol. 172, no. 1, pp. 27–36, 2001.
- A. L. Pecora, N. Rizvi, G. I. Cohen et al., “Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers,” Journal of Clinical Oncology, vol. 20, no. 9, pp. 2251–2266, 2002.
- A. M. Alabsi, S. A. Abu Bakar, R. Ali et al., “Effects of newcastle disease virus strains AF2240 and V4-UPM on cytolysis and apoptosis of leukemia cell lines,” International Journal of Molecular Sciences, vol. 12, no. 12, pp. 8645–8660, 2012.
- M. M. Zulkifli, R. Ibrahim, A. M. Ali et al., “Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma,” Neurological Research, vol. 31, no. 1, pp. 3–10, 2009.
- O. O. Kanu, B. Hughes, C. Di et al., “Glioblastoma multiforme oncogenomics and signaling pathways,” Clinical Medicine: Oncology, vol. 2009, no. 3, pp. 39–52, 2009.
- M. Nakada, D. Kita, T. Watanabe et al., “Aberrant signaling pathways in glioma,” Cancers, vol. 3, no. 3, pp. 3242–3278, 2011.
- A. Y. Chan, S. J. Coniglio, Y. Y. Chuang et al., “Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion,” Oncogene, vol. 24, no. 53, pp. 7821–7829, 2005.
- O. Gjoerup, J. Lukas, J. Bartek, and B. M. Willumsen, “Rac and Cdc42 are potent stimulators of E2F-dependent transcription capable of promoting retinoblastoma susceptibility gene product hyperphosphorylation,” The Journal of Biological Chemistry, vol. 273, no. 30, pp. 18812–18818, 1998.
- D. L. Senger, C. Tudan, M. C. Guiot et al., “Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes,” Cancer Research, vol. 62, no. 7, pp. 2131–2140, 2002.
- P. Villalonga, R. M. Guasch, K. Riento, and A. J. Ridley, “RhoE inhibits cell cycle progression and Ras-induced transformation,” Molecular and Cellular Biology, vol. 24, no. 18, pp. 7829–7840, 2004.
- D. Sun, D. Xu, and B. Zhang, “Rac signaling in tumorigenesis and as target for anticancer drug development,” Drug Resistance Updates, vol. 9, no. 6, pp. 274–287, 2006.
- B. Everts and H. G. van der Poel, “Replication-selective oncolytic viruses in the treatment of cancer,” Cancer Gene Therapy, vol. 12, no. 2, pp. 141–161, 2005.
- J. Puhlmann, F. Puehler, D. Mumberg, P. Boukamp, and R. Beier, “Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus,” Oncogene, vol. 29, no. 15, pp. 2205–2216, 2010.
- L. W. McGinnes, H. Pantua, J. Reitter, and T. G. Morrison, “UNIT 15F.2 newcastle disease virus: propagation, quantification, and storage,” Current Protocols in Microbiology, 2006.
- U. Musshoff, R. Köhling, A. Lücke et al., “Vigabatrin reduces epileptiform activity in brain slices from pharmacoresistant epilepsy patients,” European Journal of Pharmacology, vol. 401, no. 2, pp. 167–172, 2000.
- A. Bordey and H. Sontheimer, “Electrophysiological properties of human astrocytic tumor cells in situ: enigma of spiking glial cells,” Journal of Neurophysiology, vol. 79, no. 5, pp. 2782–2793, 1998.
- J. S. Diallo, D. Roy, H. Abdelbary, N. De Silva, and J. C. Bell, “Ex vivo infection of live tissue with oncolytic viruses,” Journal of Visualized Experiments, no. 52, Article ID e2854, 2011.
- K. L. Chaichana, V. Capilla-Gonzalez, O. Gonzalez-Perez et al., “Preservation of glial cytoarchitecture from ex vivo human tumor and non-tumor cerebral cortical explants: a human model to study neurological diseases,” Journal of Neuroscience Methods, vol. 164, no. 2, pp. 261–270, 2007.
- J. Xu, D. Sampath, F. F. Lang et al., “Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures,” Journal of Neuro-Oncology, vol. 105, no. 2, pp. 241–251, 2011.
- V. M. Paulino, Z. Yang, J. Kloss et al., “TROY (TNFRSF19) is overexpressed in advanced glial tumors and promotes glioblastoma cell invasion via Pyk2-Rac1 signaling,” Molecular Cancer Research, vol. 8, no. 11, pp. 1558–1567, 2010.
- G. Fulci and B. Passer, “Analysis of HSV oncolytic virotherapy in organotypic cultures,” Methods in Molecular Biology, vol. 542, pp. 75–86, 2009.
- V. P. Gopinath, G. D. Raj, A. Raja, K. Kumanan, and S. Elankumaran, “Rapid detection of newcastle disease virus replication in embryonated chicken eggs using quantitative real time polymerase chain reaction,” Journal of Virological Methods, vol. 171, no. 1, pp. 98–101, 2011.
- N. Wakamatsu, D. J. King, B. S. Seal, and C. C. Brown, “Detection of newcastle disease virus RNA by reverse transcription-polymerase chain reaction using formalin-fixed, paraffin-embedded tissue and comparison with immunohistochemistry and in situ hybridization,” Journal of Veterinary Diagnostic Investigation, vol. 19, no. 4, pp. 396–400, 2007.
- M. W. Pfaffl, G. W. Horgan, and L. Dempfle, “Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR,” Nucleic Acids Research, vol. 30, no. 9, article e36, 2002.
- V. Schirrmacher, C. Haas, R. Bonifer, T. Ahlert, R. Gerhards, and C. Ertel, “Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using newcastle disease virus,” Gene Therapy, vol. 6, no. 1, pp. 63–73, 1999.
- R. M. Lorence, B. B. Katubig, K. W. Reichard et al., “Complete regression of human fibrosarcoma xenografts after local newcastle disease virus therapy,” Cancer Research, vol. 54, no. 23, pp. 6017–6021, 1994.
- K. Pruitt and C. J. Der, “Ras and Rho regulation of the cell cycle and oncogenesis,” Cancer Letters, vol. 171, no. 1, pp. 1–10, 2001.
- L. Lossi, S. Alasia, C. Salio, and A. Merighi, “Cell death and proliferation in acute slices and organotypic cultures of mammalian CNS,” Progress in Neurobiology, vol. 88, no. 4, pp. 221–245, 2009.
- X. Li, J. W. S. Law, and A. Y. W. Lee, “Semaphorin 5A and plexin-B3 regulate human glioma cell motility and morphology through Rac1 and the actin cytoskeleton,” Oncogene, vol. 31, no. 5, pp. 595–610, 2012.